Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 742 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06186401RecruitingPhase 1
Experimental immune cell therapy for a specific type of brain cancer
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT04853342RecruitingPhase 3
Furmonertinib after lung tumor removal for EGFR-mutated lung cancer
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Suzhou, JiangsuAges 18–75 - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT07593248Recruiting
Real-World Lung Cancer Outcomes With Targeted Drug Therapy in China
This study looks at how well patients with early-stage lung cancer (that has been surgically removed) do when treated with a targeted drug called EGFR-TKI to prevent cancer from coming back. Researchers will track actual patient outcomes in China from 2023 to 2026.
BeijingAges 18 years+ - NCT06416410RecruitingPhase 3
Combination targeted therapy for KRAS G12C lung cancer
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hefei, AnhuiAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT05276726RecruitingPhase 1/Phase 2
Test drug JAB-21822 for KRAS G12C NSCLC with STK11
This trial studies how well the drug JAB-21822 works in people with advanced or spread lung cancer (NSCLC) that has a specific genetic change: KRAS G12C, plus STK11 and no KEAP1 change. It’s designed to see safety and early signs of effectiveness, especially if you haven’t been treated much yet.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06797336RecruitingPhase 1
Study of PT0253 for advanced KRAS G12D mutated tumors
This trial tests an experimental drug called PT0253 for people with advanced or metastatic cancers that have a specific genetic change called KRAS G12D. The drug may help shrink or slow the growth of these tumors, and the study will also check for side effects.
Los Angeles, CaliforniaAges 18 years+ - NCT07260175RecruitingPhase 2
Ivosidenib maintenance for IDH1-mutated bile duct cancer
This trial tests a targeted pill called ivosidenib for people with a specific type of bile duct cancer (IDH1-mutated) who have completed surgery and chemotherapy. The goal is to see if taking ivosidenib as a maintenance therapy helps keep the cancer from coming back.
AachenAges 18 years+ - NCT05640999RecruitingPhase 2
Trial for early uterine cancer with POLE mutation after surgery
This Phase 2 trial studies an added (adjuvant) treatment for early-stage uterine cancer that has a specific genetic change called POLE mutation and does not have a p53 abnormal pattern. The goal is to lower the risk of the cancer coming back after surgery.
Anchorage, AlaskaAges 18 years+ - NCT07347600Recruiting
Studying inavolisib for a type of advanced breast cancer
This study tests a targeted therapy called inavolisib for people whose breast cancer has spread (advanced or metastatic), is hormone receptor-positive and HER2-negative, has a PIK3CA mutation, and has stopped responding to hormone therapy. It aims to see if inavolisib is safe and works well for them.
Xiamen, FujianAges 18 years+ - NCT04858334RecruitingPhase 2
Olaparib after pancreatic cancer surgery for BRCA or PALB2 mutations
This trial studies whether olaparib (a targeted cancer medicine) can help prevent pancreatic cancer from coming back after surgery in people with BRCA1, BRCA2, or PALB2 mutations. You would get olaparib or a placebo (inactive pill) and be closely followed to see if recurrence is reduced.
Anchorage, AlaskaAges 18 years+ - NCT06240754RecruitingPhase 2
Study of enasidenib for low blood counts with IDH2 mutation
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
St Louis, MissouriAges 18 years+ - NCT07188740RecruitingPhase 1
Metformin to target leukemia-related mutation during remission
This trial tests if metformin can reduce a specific mutation (DNMT3A R882) in people with acute leukemia who are in remission. The goal is to see if it helps prevent relapse.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07750067RecruitingPhase 2
Combination therapy for advanced melanoma with NRAS mutation
This trial tests a combination of three drugs (tunlametinib, pucotenlimab, and hydroxychloroquine) for people with advanced melanoma that has a specific genetic change called NRAS. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Guangzhou, GuangdongAges 18 years+ - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT06529250Recruiting
Medium-dose chemo for CEBPA double-mutated AML
This trial tests a medium-dose combination of three chemotherapy drugs (homoharringtonine, cytarabine, and daunorubicin) specifically for people with a newly diagnosed type of AML that has two common CEBPA gene mutations. It aims to see if this treatment works well and is safe.
Tianjin, Tianjin MunicipalityAges 14–54 - NCT07751991RecruitingPhase 1
Study of a new drug for relapsed AML with specific genetic changes
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Grand Rapids, MichiganAges 18 years+ - NCT07566052RecruitingPhase 3
Comparing a new KRAS drug to docetaxel for advanced lung cancer
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
Glendale, CaliforniaAges 18 years+ - NCT04251052Recruiting
Compare two surgeries to lower ovarian cancer risk in BRCA1 carriers
This study compares two risk-reducing surgery plans for people with a BRCA1 genetic change to see which approach helps lower ovarian cancer risk. You may be asked to have the study procedure sooner or later depending on your chosen plan.
Birmingham, AlabamaAges 35–50 - NCT06227377RecruitingPhase 1
A new drug for cancers with KRAS G12D mutation
This trial tests a new drug called QTX3034 in people whose cancer has a specific genetic change called KRAS G12D. The drug aims to block the mutated protein that helps cancer grow, and may work even if other treatments have stopped working.
Los Angeles, CaliforniaAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Anchorage, AlaskaAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 742 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.